Relevance of JAK2V617F positivity to hematological diseases - Survey of samples from a clinical genetics laboratory

Journal of Hematology and Oncology

Volumn 4, Issue , 2011, Pages

  Zhao, Wanming ^a   Gao, Rufei ^a,b   Lee, Jiyun ^a   Xing, Shu ^a,b   Ho, Wanting T ^a   Fu, Xueqi ^b   Li, Shibo ^a   Zhao, Zhizhuang J ^a,b  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b JILIN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

JANUS KINASE; JANUS KINASE 2V617F; UNCLASSIFIED DRUG; JAK2 PROTEIN, HUMAN; JANUS KINASE 2;

AMNION FLUID ANALYSIS; ARTICLE; BLOOD SAMPLING; BONE MARROW EXAMINATION; CHROMOSOME ABERRATION; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DNA EXTRACTION; HEMATOLOGIC DISEASE; HUMAN; HUMAN CELL; LABORATORY DIAGNOSIS; MAJOR CLINICAL STUDY; MYELOPROLIFERATIVE DISORDER; POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; ADULT; AGED; ALLELE; AMNION FLUID; BLOOD; BONE MARROW; ENZYMOLOGY; FEMALE; GENETICS; MALE; METABOLISM; MIDDLE AGED;

ADULT; AGED; AGED, 80 AND OVER; ALLELES; AMNIOTIC FLUID; BONE MARROW; FEMALE; HEMATOLOGIC DISEASES; HUMANS; JANUS KINASE 2; MALE; MIDDLE AGED; MYELOPROLIFERATIVE DISORDERS; POLYMERASE CHAIN REACTION;

EID: 78651376394     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/1756-8722-4-4     Document Type: Article

References (22)

1. Classification and diagnosis of myeloproliferative neoplasms according to the 2008 World Health Organization criteria. M Wadleigh A Tefferi, Int J Hematol 2010 91 174 9 10.1007/s12185-010-0529-5 20191332
2. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. C James V Ugo JP Le Couédic J Staerk F Delhommeau C Lacout L Garçon H Raslova R Berger A Bennaceur-Griscelli JL Villeval SN Constantinescu N Casadevall W Vainchenker, Nature 2005 434 1144 1148 10.1038/nature03546 15793561 (Pubitemid 40663494)
3. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. EJ Baxter LM Scott PJ Campbell C East N Fourouclas S Swanton GS Vassiliou AJ Bench EM Boyd N Curtin MA Scott WN Erber AR Green Cancer Genome Project, Lancet 2005 365 1054 1061 15781101
4. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. RL Levine M Wadleigh J Cools BL Ebert G Wernig BJ Huntly TJ Boggon I Wlodarska JJ Clark S Moore J Adelsperger S Koo JC Lee S Gabriel T Mercher A D'Andrea S Fröhling K Döhner P Marynen P Vandenberghe RA Mesa A Tefferi JD Griffin MJ Eck WR Sellers M Meyerson TR Golub SJ Lee DG Gilliland, Cancer Cell 2005 7 387 397 10.1016/j.ccr.2005.03.023 15837627
5. A gain-of-function mutation of JAK2 in myeloproliferative disorders. R Kralovics F Passamonti AS Buser SS Teo R Tiedt JR Passweg A Tichelli M Cazzola RC Skoda, N Engl J Med 2005 352 1779 1790 10.1056/NEJMoa051113 15858187 (Pubitemid 40570926)
6. Identification of an acquired JAK2 mutation in polycythemia vera. R Zhao S Xing Z Li X Fu Q Li SB Krantz ZJ Zhao, J Biol Chem 2005 280 22788 22792 10.1074/jbc.C500138200 15863514
7. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. A Tefferi, Leukemia 2010 24 1128 38 10.1038/leu.2010.69 20428194
8. Development of ET, primary myelofibrosis and PV in mice expressing JAK2 V617F. K Shide HK Shimoda T Kumano K Karube T Kameda K Takenaka S Oku H Abe KS Katayose Y Kubuki K Kusumoto S Hasuike Y Tahara K Nagata T Matsuda K Ohshima M Harada K Shimoda, Leukemia 2008 22 87 95 10.1038/sj.leu.2405043 18033315
9. Ratio of mutant JAK2-V617F to wild type JAK2 determines the MPD phenotypes in transgenic mice. R Tiedt H Hao-Shen MA Sobas R Looser S Dirnhofer J Schwaller RC Skoda, Blood 2008 111 3931 3940 10.1182/blood-2007-08-107748 18160670
10. Transgenic expression of JAK2V617F causes myeloproliferative disorders in mice. S Xing TH Wanting W Zhao J Ma S Wang X Xu Q Li X Fu M Xu ZJ Zhao, Blood 2008 111 5109 5117 10.1182/blood-2007-05-091579 18334677
11. Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells. A Mullally SW Lane B Ball C Megerdichian R Okabe F Al-Shahrour M Paktinat JE Haydu E Housman AM Lord G Wernig MG Kharas T Mercher JL Kutok DG Gilliland BL Ebert, Cancer Cell 2010 17 584 596 10.1016/j.ccr.2010.05.015 20541703
12. Myeloproliferative neoplasm induced by constitutive expression of JAK2V617F in knock-in mice. C Marty C Lacout A Martin S Hasan S Jacquot MC Birling W Vainchenker JL Villeval, Blood 2010 116 783 787 10.1182/blood-2009-12- 257063 20472827
13. Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease. H Akada D Yan H Zou S Fiering RE Hutchison MG Mohi, Blood 2010 115 3589 3597 10.1182/blood-2009-04-215848 20197548
14. JAK2 V617F impairs hematopoietic stem cell function in a conditional knock-in mouse model of JAK2 V617F-positive essential thrombocythemia. J Li D Spensberger JS Ahn S Anand PA Beer C Ghevaert E Chen A Forrai LM Scott R Ferreira PJ Campbell SP Watson P Liu WN Erber BJ Huntly K Ottersbach AR Green, Blood 2010 116 1528 1538 10.1182/blood-2009-12-259747 20489053
15. Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. RL Levine A Pardanani A Tefferi DG Gilliland, Nat Rev Cancer 2007 7 673 683 10.1038/nrc2210 17721432
16. A Role for JAK2 Mutations in Myeloproliferative Diseases. KJ Morgan DG Gilliland, Annu Rev Med 2008 59 213 222 10.1146/annurev.med.59.061506.154159 17919086
17. JAK2V617F and phenotype: questions galore. A Pardanani, Blood 2007 109 8 10.1182/blood-2006-10-050914 (Pubitemid 46053033)
18. JAK2(V617F): Prevalence in a large Chinese hospital population. X Xu Q Zhang J Luo S Xing Q Li SB Krantz X Fu ZJ Zhao, Blood 2007 109 339 342 10.1182/blood-2006-03-009472 16946305 (Pubitemid 46053075)
19. The JAK2V617F mutation is detectable at very low level in peripheral blood of healthy donors. P Sidon H El Housni B Dessars P Heimann, Leukemia 2006 20 1622 10.1038/sj.leu.2404292 16775613
20. Mitelman Database of Chromosome Aberrations and Gene Fusions in Cancer. F Mitelman B Johansson F Mertens (Eds), 2010 http://cgap.nci.nih.gov/Chromosomes/ Mitelman
21. Myeloproliferative disorders: a practical review. LD Talarico, Patient Care 1998 30 37 57
22. A JAK2-V617F activating mutation in addition to KIT and FLT3 mutations is associated with clinical outcome in patients with t(8;21)(q22;q22) acute myeloid leukemia. E Iwanaga T Nanri N Matsuno T Kawakita H Mitsuya N Asou, Haematologica 2009 94 433 435 10.3324/haematol.13283 19181784